

SENATE CHAMBER
STATE OF OKLAHOMA

DISPOSITION

☐ FLOOR AMENDMENT

No. _____

☐ COMMITTEE AMENDMENT

(Date)

Mr./Madame President:

I move to amend Senate Bill No. 1598, by substituting the attached floor substitute for the title, enacting clause and entire body of the measure.

Submitted by:

Senator Rosino

Rosino-CB-FS-Req#3984
3/10/2020 10:58 AM

(Floor Amendments Only) Date and Time Filed: _____

☐ Untimely

☐ Amendment Cycle Extended

☐ Secondary Amendment

STATE OF OKLAHOMA

2nd Session of the 57th Legislature (2020)

FLOOR SUBSTITUTE
FOR

SENATE BILL NO. 1598

By: Rosino of the Senate

and

Hill of the House

FLOOR SUBSTITUTE

[insurance - coverage for certain disorder - terms -
codification - effective date]

BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

SECTION 1. NEW LAW A new section of law to be codified
in the Oklahoma Statutes as Section 6060.25 of Title 36, unless
there is created a duplication in numbering, reads as follows:

A. Every health benefit plan that is issued or renewed after
November 1, 2020, shall include coverage for auto-antibody and
calcium calmodulin dependent protein kinase II cell-based testing,
limited to one testing panel per year, for pediatric autoimmune
neuropsychiatric disorders associated with streptococcal or other
infections in pediatric acute onset neuropsychiatric syndrome when
the covered person has:

1 1. Neuropsychiatric symptoms that do not respond to treatment
2 within forty-five (45) days of first administered treatment; or

3 2. The diagnosis of an infection or illness within the previous
4 five (5) years; and

5 3. Testing has been ordered by:

6 a. a physician licensed under either the Oklahoma
7 Allopathic Medical and Surgical Licensure and
8 Supervision Act or the Oklahoma Osteopathic Medicine
9 Act,

10 b. an advanced practice registered nurse, as defined in
11 Section 567.3a of Title 59 of the Oklahoma Statutes,
12 or

13 c. a physician assistant, as defined in Section 519.2 of
14 Title 59 of the Oklahoma Statutes.

15 B. A health benefit plan may require prior authorization or any
16 other utilization review to ensure the criteria required by Section
17 A of this section are met.

18 C. Coverage required under this section shall be subject to a
19 maximum benefit of One Thousand Dollars (\$1,000.00) billing rate per
20 benefit plan year.

21 D. As used in this section, "health benefit plan" means any
22 plan or arrangement as defined in subsection C of Section 6060.4 of
23 Title 36 of the Oklahoma Statutes, the Oklahoma Employees Insurance
24 Plan and the state Medicaid program.

1 E. Benefits provided pursuant to subsection A of this section
2 shall not be subject to a deductible, co-payment or coinsurance
3 requirement, regardless of whether the testing provider is within or
4 outside of the network.

5 F. The Insurance Commission shall promulgate rules necessary to
6 implement the provisions of this section.

7 G. In the event the auto-antibody and calcium calmodulin
8 dependent protein Kinase II cell-based testing described in
9 subsection A of this section is not recognized by the American
10 Academy of Pediatrics within five (5) years of the effective date of
11 this act, the provisions of this section shall sunset.

12 SECTION 2. This act shall become effective November 1, 2020.

13
14 57-2-3984 CB 3/10/2020 10:58:31 AM

15
16
17
18
19
20
21
22
23
24